In this report, the EMEA Oncology Biosimilars market is valued at USD XX million in 2016 and is expected to reach USD XX million by the end of 2022, growing at a CAGR of XX% between 2016 and 2022.
Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (MT), revenue (Million USD), market share and growth rate of Oncology Biosimilars for these regions, from 2012 to 2022 (forecast)
Europe: Germany, France, UK, Russia, Italy and Benelux;
Middle East: Saudi Arabia, Israel, UAE and Iran;
Africa: South Africa, Nigeria, Egypt and Algeria.
EMEA Oncology Biosimilars market competition by top manufacturers/players, with Oncology Biosimilars sales volume (MT), price (USD/Kg), revenue (Million USD) and market share for each manufacturer/player; the top players including
Celltrion Inc.
Pfizer Inc.
Biocon
BIOCAD
Apotex Inc.
Dr. Reddy’s Laboratories Ltd.
Sandoz International GmbH
Intas Pharmaceuticals Ltd.
STADA Arzneimittel AG
Teva Pharmaceutical Industries Ltd.
On the basis of product, this report displays the sales volume (MT), revenue (Million USD), product price (USD/Kg), market share and growth rate of each type, primarily split into
G-CSF
Hematopoietic Agents
Monoclonal Antibodies
On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume (MT), market share and growth rate of Oncology Biosimilars for each application, including
Retail Pharmacies
Hospital Pharmacies
Online Pharmacies
If you have any special requirements, please let us know and we will offer you the report as you want.
Table of Contents
EMEA (Europe, Middle East and Africa) Oncology Biosimilars Market Report 2017
1 Oncology Biosimilars Overview
1.1 Product Overview and Scope of Oncology Biosimilars
1.2 Classification of Oncology Biosimilars
1.2.1 EMEA Oncology Biosimilars Market Size (Sales) Comparison by Type (2012-2022)
1.2.2 EMEA Oncology Biosimilars Market Size (Sales) Market Share by Type (Product Category) in 2016
1.2.3 G-CSF
1.2.4 Hematopoietic Agents
1.2.5 Monoclonal Antibodies
1.3 EMEA Oncology Biosimilars Market by Application/End Users
1.3.1 EMEA Oncology Biosimilars Sales (Volume) and Market Share Comparison by Application (2012-2022
1.3.2 Retail Pharmacies
1.3.3 Hospital Pharmacies
1.3.4 Online Pharmacies
1.4 EMEA Oncology Biosimilars Market by Region
1.4.1 EMEA Oncology Biosimilars Market Size (Value) Comparison by Region (2012-2022)
1.4.2 Europe Status and Prospect (2012-2022)
1.4.3 Middle East Status and Prospect (2012-2022)
1.4.4 Africa Status and Prospect (2012-2022)
1.5 EMEA Market Size (Value and Volume) of Oncology Biosimilars (2012-2022)
1.5.1 EMEA Oncology Biosimilars Sales and Growth Rate (2012-2022)
1.5.2 EMEA Oncology Biosimilars Revenue and Growth Rate (2012-2022)
2 EMEA Oncology Biosimilars Competition by Manufacturers/Players/Suppliers, Region, Type and Application
2.1 EMEA Oncology Biosimilars Market Competition by Players/Manufacturers
2.1.1 EMEA Oncology Biosimilars Sales Volume and Market Share of Major Players (2012-2017)
2.1.2 EMEA Oncology Biosimilars Revenue and Share by Players (2012-2017)
2.1.3 EMEA Oncology Biosimilars Sale Price by Players (2012-2017)
2.2 EMEA Oncology Biosimilars (Volume and Value) by Type/Product Category
2.2.1 EMEA Oncology Biosimilars Sales and Market Share by Type (2012-2017)
2.2.2 EMEA Oncology Biosimilars Revenue and Market Share by Type (2012-2017)
2.2.3 EMEA Oncology Biosimilars Sale Price by Type (2012-2017)
2.3 EMEA Oncology Biosimilars (Volume) by Application
2.4 EMEA Oncology Biosimilars (Volume and Value) by Region
2.4.1 EMEA Oncology Biosimilars Sales and Market Share by Region (2012-2017)
2.4.2 EMEA Oncology Biosimilars Revenue and Market Share by Region (2012-2017)
2.4.3 EMEA Oncology Biosimilars Sales Price by Region (2012-2017)
3 Europe Oncology Biosimilars (Volume, Value and Sales Price), by Players, Countries, Type and Application
3.1 Europe Oncology Biosimilars Sales and Value (2012-2017)
3.1.1 Europe Oncology Biosimilars Sales Volume and Growth Rate (2012-2017)
3.1.2 Europe Oncology Biosimilars Revenue and Growth Rate (2012-2017)
3.2 Europe Oncology Biosimilars Sales and Market Share by Type
3.3 Europe Oncology Biosimilars Sales and Market Share by Application
3.4 Europe Oncology Biosimilars Sales Volume and Value (Revenue) by Countries
3.4.1 Europe Oncology Biosimilars Sales Volume by Countries (2012-2017)
3.4.2 Europe Oncology Biosimilars Revenue by Countries (2012-2017)
3.4.3 Germany Oncology Biosimilars Sales and Growth Rate (2012-2017)
3.4.4 France Oncology Biosimilars Sales and Growth Rate (2012-2017)
3.4.5 UK Oncology Biosimilars Sales and Growth Rate (2012-2017)
3.4.6 Russia Oncology Biosimilars Sales and Growth Rate (2012-2017)
3.4.7 Italy Oncology Biosimilars Sales and Growth Rate (2012-2017)
3.4.8 Benelux Oncology Biosimilars Sales and Growth Rate (2012-2017)
4 Middle East Oncology Biosimilars (Volume, Value and Sales Price), by Region, Type and Application
4.1 Middle East Oncology Biosimilars Sales and Value (2012-2017)
4.1.1 Middle East Oncology Biosimilars Sales Volume and Growth Rate (2012-2017)
4.1.2 Middle East Oncology Biosimilars Revenue and Growth Rate (2012-2017)
4.2 Middle East Oncology Biosimilars Sales and Market Share by Type
4.3 Middle East Oncology Biosimilars Sales and Market Share by Application
4.4 Middle East Oncology Biosimilars Sales Volume and Value (Revenue) by Countries
4.4.1 Middle East Oncology Biosimilars Sales Volume by Countries (2012-2017)
4.4.2 Middle East Oncology Biosimilars Revenue by Countries (2012-2017)
4.4.3 Saudi Arabia Oncology Biosimilars Sales and Growth Rate (2012-2017)
4.4.4 Israel Oncology Biosimilars Sales and Growth Rate (2012-2017)
4.4.5 UAE Oncology Biosimilars Sales and Growth Rate (2012-2017)
4.4.6 Iran Oncology Biosimilars Sales and Growth Rate (2012-2017)
5 Africa Oncology Biosimilars (Volume, Value and Sales Price) by Players, Countries, Type and Application
5.1 Africa Oncology Biosimilars Sales and Value (2012-2017)
5.1.1 Africa Oncology Biosimilars Sales Volume and Growth Rate (2012-2017)
5.1.2 Africa Oncology Biosimilars Revenue and Growth Rate (2012-2017)
5.2 Africa Oncology Biosimilars Sales and Market Share by Type
5.3 Africa Oncology Biosimilars Sales and Market Share by Application
5.4 Africa Oncology Biosimilars Sales Volume and Value (Revenue) by Countries
5.4.1 Africa Oncology Biosimilars Sales Volume by Countries (2012-2017)
5.4.2 Africa Oncology Biosimilars Revenue by Countries (2012-2017)
5.4.3 South Africa Oncology Biosimilars Sales and Growth Rate (2012-2017)
5.4.4 Nigeria Oncology Biosimilars Sales and Growth Rate (2012-2017)
5.4.5 Egypt Oncology Biosimilars Sales and Growth Rate (2012-2017)
5.4.6 Algeria Oncology Biosimilars Sales and Growth Rate (2012-2017)
6 EMEA Oncology Biosimilars Manufacturers/Players Profiles and Sales Data
6.1 Celltrion Inc.
6.1.1 Company Basic Information, Manufacturing Base and Competitors
6.1.2 Oncology Biosimilars Product Type, Application and Specification
6.1.2.1 Product A
6.1.2.2 Product B
6.1.3 Celltrion Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.1.4 Main Business/Business Overview
6.2 Pfizer Inc.
6.2.1 Company Basic Information, Manufacturing Base and Competitors
6.2.2 Oncology Biosimilars Product Type, Application and Specification
6.2.2.1 Product A
6.2.2.2 Product B
6.2.3 Pfizer Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.2.4 Main Business/Business Overview
6.3 Biocon
6.3.1 Company Basic Information, Manufacturing Base and Competitors
6.3.2 Oncology Biosimilars Product Type, Application and Specification
6.3.2.1 Product A
6.3.2.2 Product B
6.3.3 Biocon Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.3.4 Main Business/Business Overview
6.4 BIOCAD
6.4.1 Company Basic Information, Manufacturing Base and Competitors
6.4.2 Oncology Biosimilars Product Type, Application and Specification
6.4.2.1 Product A
6.4.2.2 Product B
6.4.3 BIOCAD Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.4.4 Main Business/Business Overview
6.5 Apotex Inc.
6.5.1 Company Basic Information, Manufacturing Base and Competitors
6.5.2 Oncology Biosimilars Product Type, Application and Specification
6.5.2.1 Product A
6.5.2.2 Product B
6.5.3 Apotex Inc. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.5.4 Main Business/Business Overview
6.6 Dr. Reddy’s Laboratories Ltd.
6.6.1 Company Basic Information, Manufacturing Base and Competitors
6.6.2 Oncology Biosimilars Product Type, Application and Specification
6.6.2.1 Product A
6.6.2.2 Product B
6.6.3 Dr. Reddy’s Laboratories Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.6.4 Main Business/Business Overview
6.7 Sandoz International GmbH
6.7.1 Company Basic Information, Manufacturing Base and Competitors
6.7.2 Oncology Biosimilars Product Type, Application and Specification
6.7.2.1 Product A
6.7.2.2 Product B
6.7.3 Sandoz International GmbH Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.7.4 Main Business/Business Overview
6.8 Intas Pharmaceuticals Ltd.
6.8.1 Company Basic Information, Manufacturing Base and Competitors
6.8.2 Oncology Biosimilars Product Type, Application and Specification
6.8.2.1 Product A
6.8.2.2 Product B
6.8.3 Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.8.4 Main Business/Business Overview
6.9 STADA Arzneimittel AG
6.9.1 Company Basic Information, Manufacturing Base and Competitors
6.9.2 Oncology Biosimilars Product Type, Application and Specification
6.9.2.1 Product A
6.9.2.2 Product B
6.9.3 STADA Arzneimittel AG Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.9.4 Main Business/Business Overview
6.10 Teva Pharmaceutical Industries Ltd.
6.10.1 Company Basic Information, Manufacturing Base and Competitors
6.10.2 Oncology Biosimilars Product Type, Application and Specification
6.10.2.1 Product A
6.10.2.2 Product B
6.10.3 Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales, Revenue, Price and Gross Margin (2012-2017)
6.10.4 Main Business/Business Overview
7 Oncology Biosimilars Manufacturing Cost Analysis
7.1 Oncology Biosimilars Key Raw Materials Analysis
7.1.1 Key Raw Materials
7.1.2 Price Trend of Key Raw Materials
7.1.3 Key Suppliers of Raw Materials
7.1.4 Market Concentration Rate of Raw Materials
7.2 Proportion of Manufacturing Cost Structure
7.2.1 Raw Materials
7.2.2 Labor Cost
7.2.3 Manufacturing Expenses
7.3 Manufacturing Process Analysis of Oncology Biosimilars
8 Industrial Chain, Sourcing Strategy and Downstream Buyers
8.1 Oncology Biosimilars Industrial Chain Analysis
8.2 Upstream Raw Materials Sourcing
8.3 Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2016
8.4 Downstream Buyers
9 Marketing Strategy Analysis, Distributors/Traders
9.1 Marketing Channel
9.1.1 Direct Marketing
9.1.2 Indirect Marketing
9.1.3 Marketing Channel Development Trend
9.2 Market Positioning
9.2.1 Pricing Strategy
9.2.2 Brand Strategy
9.2.3 Target Client
9.3 Distributors/Traders List
10 Market Effect Factors Analysis
10.1 Technology Progress/Risk
10.1.1 Substitutes Threat
10.1.2 Technology Progress in Related Industry
10.2 Consumer Needs/Customer Preference Change
10.3 Economic/Political Environmental Change
11 EMEA Oncology Biosimilars Market Forecast (2017-2022)
11.1 EMEA Oncology Biosimilars Sales, Revenue and Price Forecast (2017-2022)
11.1.1 EMEA Oncology Biosimilars Sales and Growth Rate Forecast (2017-2022)
11.1.2 EMEA Oncology Biosimilars Revenue and Growth Rate Forecast (2017-2022)
11.1.3 EMEA Oncology Biosimilars Price and Trend Forecast (2017-2022)
11.2 EMEA Oncology Biosimilars Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.3 Europe Oncology Biosimilars Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.4 Middle Eastt Oncology Biosimilars Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.5 Africa Oncology Biosimilars Sales, Revenue and Growth Rate Forecast by Region (2017-2022)
11.6 EMEA Oncology Biosimilars Sales Forecast by Type (2017-2022)
11.7 EMEA Oncology Biosimilars Sales Forecast by Application (2017-2022)
12 Research Findings and Conclusion
13 Appendix
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
List of Tables and Figures
Figure Product Picture of Oncology Biosimilars
Figure EMEA Oncology Biosimilars Sales Volume (MT) by Type (2012-2022)
Figure EMEA Oncology Biosimilars Sales Volume Market Share by Type (Product Category) in 2016
Figure G-CSF Product Picture
Figure Hematopoietic Agents Product Picture
Figure Monoclonal Antibodies Product Picture
Figure EMEA Oncology Biosimilars Sales Volume (MT) by Application (2012-2022)
Figure EMEA Sales Market Share of Oncology Biosimilars by Application in 2016
Figure Retail Pharmacies Examples
Table Key Downstream Customer in Retail Pharmacies
Figure Hospital Pharmacies Examples
Table Key Downstream Customer in Hospital Pharmacies
Figure Online Pharmacies Examples
Table Key Downstream Customer in Online Pharmacies
Figure EMEA Oncology Biosimilars Market Size (Million USD) by Region (2012-2022)
Figure Europe Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure Europe Oncology Biosimilars Revenue (Million USD) Status and Forecast by Countries
Figure Middle East Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure Middle East Oncology Biosimilars Revenue (Million USD) Status and Forecast by Countries
Figure Africa Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure Africa Oncology Biosimilars Revenue (Million USD) Status and Forecast by Countries
Figure EMEA Oncology Biosimilars Sales Volume and Growth Rate (2012-2022)
Figure EMEA Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2022)
Figure EMEA Oncology Biosimilars Market Major Players Product Sales Volume (MT) (2012-2017)
Table EMEA Oncology Biosimilars Sales Volume (MT) of Major Players (2012-2017)
Table EMEA Oncology Biosimilars Sales Share by Players (2012-2017)
Figure 2016 Oncology Biosimilars Sales Share by Players
Figure 2017 Oncology Biosimilars Sales Share by Players
Figure EMEA Oncology Biosimilars Market Major Players Product Revenue (Million USD) (2012-2017)
Table EMEA Oncology Biosimilars Revenue (Million USD) by Players (2012-2017)
Table EMEA Oncology Biosimilars Revenue Share by Players (2012-2017)
Table 2016 EMEA Oncology Biosimilars Revenue Share by Players
Table 2017 EMEA Oncology Biosimilars Revenue Share by Players
Table EMEA Oncology Biosimilars Sale Price (USD/Kg) by Players (2012-2017)
Table EMEA Oncology Biosimilars Sales (MT) and Market Share by Type (2012-2017)
Table EMEA Oncology Biosimilars Sales Share by Type (2012-2017)
Figure Sales Market Share of Oncology Biosimilars by Type (2012-2017)
Figure EMEA Oncology Biosimilars Sales Market Share by Type (2012-2017)
Table EMEA Oncology Biosimilars Revenue (Million USD) and Market Share by Type (2012-2017)
Table EMEA Oncology Biosimilars Revenue Share by Type (2012-2017)
Figure Revenue Market Share of Oncology Biosimilars by Type in 2016
Table EMEA Oncology Biosimilars Sale Price (USD/Kg) by Type (2012-2017)
Table EMEA Oncology Biosimilars Sales (MT) and Market Share by Application (2012-2017)
Table EMEA Oncology Biosimilars Sales Share by Application (2012-2017)
Figure Sales Market Share of Oncology Biosimilars by Application (2012-2017)
Figure EMEA Oncology Biosimilars Sales Market Share by Application in 2016
Table EMEA Oncology Biosimilars Sales (MT) and Market Share by Region (2012-2017)
Table EMEA Oncology Biosimilars Sales Share by Region (2012-2017)
Figure Sales Market Share of Oncology Biosimilars by Region (2012-2017)
Figure EMEA Oncology Biosimilars Sales Market Share in 2016
Table EMEA Oncology Biosimilars Revenue (Million USD) and Market Share by Region (2012-2017)
Table EMEA Oncology Biosimilars Revenue Share by Region (2012-2017)
Figure Revenue Market Share of Oncology Biosimilars by Region (2012-2017)
Figure EMEA Oncology Biosimilars Revenue Market Share Regions in 2016
Table EMEA Oncology Biosimilars Sales Price (USD/Kg) by Region (2012-2017)
Figure Europe Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Europe Oncology Biosimilars Revenue and Growth Rate (2012-2017)
Table Europe Oncology Biosimilars Sales (MT) by Type (2012-2017)
Table Europe Oncology Biosimilars Market Share by Type (2012-2017)
Figure Europe Oncology Biosimilars Market Share by Type in 2016
Table Europe Oncology Biosimilars Sales (MT) by Application (2012-2017)
Table Europe Oncology Biosimilars Market Share by Application (2012-2017)
Figure Europe Oncology Biosimilars Market Share by Application in 2016
Table Europe Oncology Biosimilars Sales (MT) by Countries (2012-2017)
Table Europe Oncology Biosimilars Sales Market Share by Countries (2012-2017)
Figure Europe Oncology Biosimilars Sales Market Share by Countries (2012-2017)
Figure Europe Oncology Biosimilars Sales Market Share by Countries in 2016
Table Europe Oncology Biosimilars Revenue (Million USD) by Countries (2012-2017)
Table Europe Oncology Biosimilars Revenue Market Share by Countries (2012-2017)
Figure Europe Oncology Biosimilars Revenue Market Share by Countries (2012-2017)
Figure Europe Oncology Biosimilars Revenue Market Share by Countries in 2016
Figure Germany Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure France Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure UK Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Russia Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Italy Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Benelux Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Middle East Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Middle East Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2017)
Table Middle East Oncology Biosimilars Sales (MT) by Type (2012-2017)
Table Middle East Oncology Biosimilars Market Share by Type (2012-2017)
Figure Middle East Oncology Biosimilars Market Share by Type (2012-2017)
Table Middle East Oncology Biosimilars Sales (MT) by Applications (2012-2017)
Table Middle East Oncology Biosimilars Market Share by Applications (2012-2017)
Figure Middle East Oncology Biosimilars Sales Market Share by Application in 2016
Table Middle East Oncology Biosimilars Sales Volume (MT) by Countries (2012-2017)
Table Middle East Oncology Biosimilars Sales Volume Market Share by Countries (2012-2017)
Figure Middle East Oncology Biosimilars Sales Volume Market Share by Countries in 2016
Table Middle East Oncology Biosimilars Revenue (Million USD) by Countries (2012-2017)
Table Middle East Oncology Biosimilars Revenue Market Share by Countries (2012-2017)
Figure Middle East Oncology Biosimilars Revenue Market Share by Countries (2012-2017)
Figure Middle East Oncology Biosimilars Revenue Market Share by Countries in 2016
Figure Saudi Arabia Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Israel Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure UAE Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Iran Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Africa Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Africa Oncology Biosimilars Revenue (Million USD) and Growth Rate (2012-2017)
Table Africa Oncology Biosimilars Sales (MT) by Type (2012-2017)
Table Africa Oncology Biosimilars Sales Market Share by Type (2012-2017)
Figure Africa Oncology Biosimilars Sales Market Share by Type (2012-2017)
Figure Africa Oncology Biosimilars Sales Market Share by Type in 2016
Table Africa Oncology Biosimilars Sales (MT) by Application (2012-2017)
Table Africa Oncology Biosimilars Sales Market Share by Application (2012-2017)
Figure Africa Oncology Biosimilars Sales Market Share by Application (2012-2017)
Table Africa Oncology Biosimilars Sales Volume (MT) by Countries (2012-2017)
Table Africa Oncology Biosimilars Sales Market Share by Countries (2012-2017)
Figure Africa Oncology Biosimilars Sales Market Share by Countries (2012-2017)
Figure Africa Oncology Biosimilars Sales Market Share by Countries in 2016
Table Africa Oncology Biosimilars Revenue (Million USD) by Countries (2012-2017)
Table Africa Oncology Biosimilars Revenue Market Share by Countries (2012-2017)
Figure Africa Oncology Biosimilars Revenue Market Share by Countries (2012-2017)
Figure Africa Oncology Biosimilars Revenue Market Share by Countries in 2016
Figure South Africa Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Nigeria Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Egypt Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Algeria Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Table Celltrion Inc. Oncology Biosimilars Basic Information List
Table Celltrion Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Celltrion Inc. Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Pfizer Inc. Oncology Biosimilars Basic Information List
Table Pfizer Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Pfizer Inc. Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Biocon Oncology Biosimilars Basic Information List
Table Biocon Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Biocon Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Biocon Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Biocon Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table BIOCAD Oncology Biosimilars Basic Information List
Table BIOCAD Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure BIOCAD Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure BIOCAD Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure BIOCAD Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Apotex Inc. Oncology Biosimilars Basic Information List
Table Apotex Inc. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Apotex Inc. Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Dr. Reddy’s Laboratories Ltd. Oncology Biosimilars Basic Information List
Table Dr. Reddy’s Laboratories Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Dr. Reddy’s Laboratories Ltd. Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Dr. Reddy’s Laboratories Ltd. Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Dr. Reddy’s Laboratories Ltd. Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Sandoz International GmbH Oncology Biosimilars Basic Information List
Table Sandoz International GmbH Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Sandoz International GmbH Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Intas Pharmaceuticals Ltd. Oncology Biosimilars Basic Information List
Table Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Intas Pharmaceuticals Ltd. Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table STADA Arzneimittel AG Oncology Biosimilars Basic Information List
Table STADA Arzneimittel AG Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure STADA Arzneimittel AG Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Basic Information List
Table Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales (MT), Revenue (Million USD), Price (USD/Kg) and Gross Margin (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales (MT) and Growth Rate (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Sales Market Share in EMEA (2012-2017)
Figure Teva Pharmaceutical Industries Ltd. Oncology Biosimilars Revenue Market Share in EMEA (2012-2017)
Table Production Base and Market Concentration Rate of Raw Material
Figure Price Trend of Key Raw Materials
Table Key Suppliers of Raw Materials
Figure Manufacturing Cost Structure of Oncology Biosimilars
Figure Manufacturing Process Analysis of Oncology Biosimilars
Figure Oncology Biosimilars Industrial Chain Analysis
Table Raw Materials Sources of Oncology Biosimilars Major Manufacturers in 2016
Table Major Buyers of Oncology Biosimilars
Table Distributors/Traders List
Figure EMEA Oncology Biosimilars Sales (MT) and Growth Rate Forecast (2017-2022)
Figure EMEA Oncology Biosimilars Revenue and Growth Rate Forecast (2017-2022)
Figure EMEA Oncology Biosimilars Price (USD/Kg) and Trend Forecast (2017-2022)
Table EMEA Oncology Biosimilars Sales (MT) Forecast by Region (2017-2022)
Figure EMEA Oncology Biosimilars Sales Market Share Forecast by Region (2017-2022)
Table EMEA Oncology Biosimilars Revenue (Million USD) Forecast by Region (2017-2022)
Figure EMEA Oncology Biosimilars Revenue Market Share Forecast by Region (2017-2022)
Table Europe Oncology Biosimilars Sales (MT) Forecast by Countries (2017-2022)
Figure Europe Oncology Biosimilars Sales Market Share Forecast by Countries (2017-2022)
Table Europe Oncology Biosimilars Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Europe Oncology Biosimilars Revenue Market Share Forecast by Countries (2017-2022)
Table Middle East Oncology Biosimilars Sales (MT) Forecast by Countries (2017-2022)
Figure Middle East Oncology Biosimilars Sales Market Share Forecast by Countries (2017-2022)
Table Middle East Oncology Biosimilars Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Middle East Oncology Biosimilars Revenue Market Share Forecast by Countries (2017-2022)
Table Africa Oncology Biosimilars Sales (MT) Forecast by Countries (2017-2022)
Figure Africa Oncology Biosimilars Sales Market Share Forecast by Countries (2017-2022)
Table Africa Oncology Biosimilars Revenue (Million USD) Forecast by Countries (2017-2022)
Figure Africa Oncology Biosimilars Revenue Market Share Forecast by Countries (2017-2022)
Table EMEA Oncology Biosimilars Sales (MT) Forecast by Type (2017-2022)
Figure EMEA Oncology Biosimilars Sales Market Share Forecast by Type (2017-2022)
Table EMEA Oncology Biosimilars Sales (MT) Forecast by Application (2017-2022)
Figure EMEA Oncology Biosimilars Sales Market Share Forecast by Application (2017-2022)
Table Research Programs/Design for This Report
Figure Bottom-up and Top-down Approaches for This Report
Figure Data Triangulation
Table Key Data Information from Secondary Sources
Table Key Data Information from Primary Sources
